A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

ClinicalTrials.gov ID: NCT03965845

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03965845. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor telaglenestat (CB-839) with the CDK4/6 Inhibitor, palbociclib in participants with advanced/metastatic solid tumors.

Study identification

NCT ID: NCT03965845
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Calithera Biosciences, Inc; Industry
Enrollment: 53 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 25, 2019 (Actual)
Primary completion: Sep 24, 2021 (Actual)
Completion: Sep 24, 2021 (Actual)
Last update posted: Sep 19, 2022

2019 – 2021

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
UCLA Hematology/Oncology	Santa Monica	California	90095	—
Emory, Winship Cancer Institute	Atlanta	Georgia	30322	—
Northwestern University Feinberg School of Medicine	Chicago	Illinois	60611	—
Rush University Medical Center	Chicago	Illinois	60612	—
University of Iowa Hospitals and Clinics	Iowa City	Iowa	52242	—
Regions Cancer care Center	Saint Paul	Minnesota	55101	—
Sarah Cannon Research Institute- Tennessee Oncology	Nashville	Tennessee	37203	—
MD Anderson	Houston	Texas	77030	—
South Texas Accelerated Research Therapeutic, LLC	San Antonio	Texas	78229	—
University of Wisconsin Clinical Science Center	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03965845, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 19, 2022 · Synced Nov 13, 2026